Phase 3 study of Mino-Lok in patients with Catheter infections

Trial Profile

Phase 3 study of Mino-Lok in patients with Catheter infections

Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Alcohol/disodium edetate/minocycline (Primary)
  • Indications Catheter infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2017 According to a Citius Pharmaceuticals Inc. media release, the US FDA has granted Fast-Track designation to the investigational program for Mino-Lok.
    • 05 Sep 2017 According to a Citius Pharmaceuticals media release, the study design has been amended to remove the saline and heparin placebo control arm and to use an active control arm that conforms with today's current standard of care. The Company also noted that the dwell times and dosing schedules of the antibiotic lock therapy (ALT) active control arm would be changed because there is an extreme level of variability and heterogeneity in how ALTs are dosed and used today.
    • 04 Oct 2016 Status changed from planning to recruiting, as per Media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top